|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data显示文摘 | Monique Maas Patty J Nelemans Vincenzo Valentini Prajnan Das Claus R?del Li-Jen Kuo Felipe A Calvo Julio García-Aguilar Rob Glynne-Jones Karin Haustermans Mohammed Mohiuddin Salvatore Pucciarelli William Small Javier Suárez George Theodoropoulos Sebastian | 2010 | Lancet Oncology2010，，9： | 1 |
| 2 | Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data显示文摘 | Monique Maas Patty J Nelemans Vincenzo Valentini Prajnan Das Claus R?del Li-Jen Kuo Felipe A Calvo Julio García-Aguilar Rob Glynne-Jones Karin Haustermans Mohammed Mohiuddin Salvatore Pucciarelli William Small Javier Suárez George Theodoropoulos Sebastian | 2010 | Lancet Oncology2010，，9： | 1 |
| 3 | Postoperative radiotherapy in resected non-small cell lung cancer:The never-ending story显示文摘This manuscript collects in a joint and orderly manner the existing evidence at the present time about postoperative treatment with radiotherapy in non-small cell lung cancer.It also systematically reviews the current evidence,the international recommendations in the most relevant guidelines,the most controversial aspects in clinical and pathological staging,the specific technical aspects of radiotherapy treatment,and also collects all the potential risk factors that have been postulated as significant in the prognosis of these patients,evaluating the possibility of segmenting a particularly sensitive subpopulation with a high risk of relapse on which an adjuvant treatment with radiotherapy could have an impact on their clinical evolution.Finally,currently active trials that aspire to provide more evidence on this topic are reviewed. | Javier Serrano Patricia Calvo Crespo Begoña Taboada Ana Alvarez Gonzalez Rafael Garcia García Antonio Gomez Caamaño Juan Carlos Trujillo Reyes Xabier Mielgo-Rubio Felipe Couñago | 2021 | World Journal of Clinical Oncology2021，12，10： | 1 |
| 4 | Multi-institutional Pooled Analysis on Adjuvant Chemoradiation in Pancreatic Cancer显示文摘 | Alessio G. Morganti Massimo Falconi Ruud G.P.M. van Stiphout Gian-Carlo Mattiucci Sergio Alfieri Felipe A. Calvo Jean-Bernard Dubois Gerd Fastner Joseph M. Herman Bert W. Maidment Robert C. Miller William F. Regine Michele Reni Navesh K. Sharma Edy Ippoli | 2014 | International Journal of Radiation Oncology, Biology, Physics2014，，： | 1 |
| 5 | Intraoperative Radiation Therapy First part:Rationale and Techniques显示文摘 | Felipe A Calvo Rosa M Meirino Roberto Orecchia | 2006 | Critical Reviews in Oncology/Hematology2006，59，： | 1 |
| 6 | Value of adeno- sine deaminase(ADA) in ascitic fluid for the diagnosis of tuberculous peritonitis显示文摘 | Amoldo Riquelme Mario Calvo Felipe Salech | 2006 | J Clin Gastroenterol2006，40，8： | 1 |
| 7 | GOECP/SEOR radiotherapy guidelines for small-cell lung cancer显示文摘Small cell lung cancer(SCLC)accounts for approximately 20%of all lung cancers.The main treatment is chemotherapy(Ch).However,the addition of radiotherapy significantly improves overall survival(OS)in patients with non-metastatic SCLC and in those with metastatic SCLC who respond to Ch.Prophylactic cranial irradiation reduces the risk of brain metastases and improves OS in both metastatic and non-metastatic patients.The 5-year OS rate in patients with limited-stage disease(non-metastatic)is slightly higher than 30%,but less than 5%in patients with extensive-stage disease(metastatic).The present clinical guidelines were developed by Spanish radiation oncologists on behalf of the Oncologic Group for the Study of Lung Cancer/Spanish Society of Radiation Oncology to provide a current review of the diagnosis,planning,and treatment of SCLC.These guidelines emphasise treatment fields,radiation techniques,fractionation,concomitant treatment,and the optimal timing of Ch and radiotherapy.Finally,we discuss the main indications for reirradiation in local recurrence. | Felipe Couñago Carolina de la Pinta Susana Gonzalo Castalia Fernández Piedad Almendros Patricia Calvo Begoña Taboada Antonio Gómez-Caamaño JoséLuis López Guerra Marisa Chust JoséAntonio GonzálezFerreira AnaÁlvarez González Francesc Casas | 2021 | World Journal of Clinical Oncology2021，12，3： | 1 |
| 8 | 18 F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation显示文摘 | Felipe A Calvo Marta Domper Raúl Matute Raúl Martínez-Lázaro José A Arranz Manuel Desco Emilio álvarez José Luis Carreras | 2004 | International Journal of Radiation Oncology Biology Physics2004，，2： | 1 |
| 9 | Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor:A new paradigm?显示文摘Stereotactic ablative body radiotherapy(SABR)is an effective technique comparable to surgery in terms of local control and efficacy in early stages of non-small cell lung cancer(NSCLC)and pulmonary metastasis.Several fractionation schemes have proven to be safe and effective,including the single fraction(SF)scheme.SF is an option costeffectiveness,more convenience and comfortable for the patient and flexible in terms of its management combined with systemic treatments.The outbreak of the severe acute respiratory syndrome coronavirus 2 pandemic has driven this not new but underutilized paradigm,recommending this option to minimize patients’visits to hospital.SF SABR already has a long experience,strong evidence and sufficient maturity to reliably evaluate outcomes in peripheral primary NSCLC and there are promising outcomes in pulmonary metastases,making it a valid treatment option;although its use in central locations,synchronous and recurrencies tumors requires more prospective safety and efficacy studies.The SABR radiobiology study,together with the combination with systemic therapies,(targeted therapies and immunotherapy)is a direction of research in both advanced disease and early stages whose future includes SF. | Castalia Fernandez Arturo Navarro-Martin Andrea Bobo Joaquin Cabrera-Rodriguez Patricia Calvo Rodolfo Chicas-Sett Javier Luna Nuria Rodriguez de Dios Felipe Counago | 2022 | World Journal of Clinical Oncology2022，13，2： | 0 |
| 10 | Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting显示文摘AIM To investigated the real-world effectiveness and safety of various regimens of interferon-free treatments in patients infected with hepatitis C virus(HCV).METHODS We performed an observational study to analyze different antiviral treatments administered to 462 HCV-infected patients, of which 56.7% had liver cirrhosis. HCV RNA after 4 wk of treatment and at 12 wk after treatment sustained virologic response(SVR) as well as serious adverse events(SAEs) was analyzed first for the whole cohort and then separately in patients who met or did not meet the inclusion criteria of a clinical trial(CT-met and CT-unmet, respectively).RESULTS The most frequently prescribed treatment was simeprevir/sofosbuvir(36.4%), followed by sofosbuvir/ledipasvir(24.9%) and ombitasvir/paritaprevir/ritonavir(r)/dasabuvir(19.9%). Ribavirin(RBV) was administered in 198 patients(42.9%). SVRs occurred in 437/462 patients(94.6%). The SVRs ranged between 93.3% and 100% for genotypes 1-4. SVRs were achieved in 96.2% patients in the CTmet group vs 91.9% patients in the CT-unmet group(P = 0.049). Undetectable HCV RNA at week 4 occurred in 72.9% of the patients. In the univariate analysis, the factors associated with SVRs were lower liver stiffness, absence of cirrhosis, higher platelet count, higher albumin levels, no RBV dose reduction, undetectable HCV RNA at week 4 and CT-met group. In the multivariate analysis, only albumin was an independent predictor of treatment failure(P = 0.04). Eleven patients(2.4%) developed SAEs; 5.2% and 0.7% of the patients in the CT-unmet and CT-met groups, respectively(P = 0.003).CONCLUSION A high proportion of patients with HCV infection achieved SVRs. For patients who did not meet the CT criteria, treatment regimens must be optimized. | Huascar Ramos Pedro Linares Ester Badia Isabel Martín Judith Gómez Carolina Almohalla Francisco Jorquera Sara Calvo Isidro García Pilar Conde Begona álvarez Guillermo Karpman Sara Lorenzo Visitación Gozalo Mónica Vásquez Diana Joao Marina de Benito Lourdes Ruiz Felipe Jiménez Federico Sáez-Royuela 无 | 2017 | World Journal of Gastrointestinal Pharmacology and Therapeutics2017，8，2： | 0 |
| 11 | Neurocognitive outcomes in pediatric brain tumors after treatment with proton versus photon radiation:a systematic review and meta-analysis显示文摘Background Advances in cancer treatments,particularly the development of radiation therapy,have led to improvements in survival outcomes in children with brain tumors.However,radiation therapy is associated with significant long-term neurocognitive morbidity.The present systematic review and meta-analysis aimed to compare the neurocognitive outcomes of children and adolescents with brain tumors treated with photon radiation(XRT)or proton therapy(PBRT).Methods A systematic search was conducted(PubMed,Embase,Cochrane,and Web of Science from inception until 02/01/2022)for studies comparing the neurocognitive outcomes of children and adolescents with brain tumors treated with XRT vs.PBRT.The pooled mean differences(expressed as Z scores)were calculated using a random effects method for those endpoints analyzed by a minimum of three studies.Results Totally 10 studies(n=630 patients,average age range:1–20 years)met the inclusion criteria.Patients who had received PBRT achieved significantly higher scores(difference in Z scores ranging from 0.29–0.75,all P<0.05 and significant in sensitivity analyses)after treatment than those who had received XRT for most analyzed neurocognitive outcomes(i.e.,intelligence quotient,verbal comprehension and perceptual reasoning indices,visual motor integration,and verbal memory).No robust significant differences(P>0.05 in main analyses or sensitivity analyses)were found for nonverbal memory,verbal working memory and working memory index,processing speed index,or focused attention.Conclusions Pediatric brain tumor patients who receive PBRT achieve significantly higher scores on most neurocognitive outcomes than those who receive XRT.Larger studies with long-term follow-ups are needed to confirm these results. | Álvaro Lassaletta Javier S.Morales Pedro L.Valenzuela Borja Esteso Lisa S.Kahalley Donald J.Mabbott Soumya Unnikrishnan Elena Panizo Felipe Calvo | 2023 | World Journal of Pediatrics2023，19，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员